RA Capital Nexus Fund III, L.P. bought $33.0M of Bicara Therapeutics (BCAX)
Executed Sep 16 2024, disclosed Sep 18 2024, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 18 2024), the stock returned -26.5% (delay-adjusted); from the execution session (Sep 16 2024), -10.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
RA Capital Nexus Fund III, L.P. (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $14.8M of SION (373,610 sh across 8 lots, as filed), executed Oct 24 2025.
Healthcare · Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→